MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
- Written by PR Newswire
SHANGHAI and HANGZHOU, China, June 14, 2023 /PRNewswire/ -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced today that the first healthy volunteer dosed in the Phase 1 study of their oral small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), MDR-001 for the treatment of obesity...
Read more: MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China